Lentiviral mediated delivery of CRISPR/Cas9 reduces intraocular pressure in a mouse model of myocilin glaucoma
- PMID: 38521856
- PMCID: PMC10960846
- DOI: 10.1038/s41598-024-57286-6
Lentiviral mediated delivery of CRISPR/Cas9 reduces intraocular pressure in a mouse model of myocilin glaucoma
Abstract
Mutations in myocilin (MYOC) are the leading known genetic cause of primary open-angle glaucoma, responsible for about 4% of all cases. Mutations in MYOC cause a gain-of-function phenotype in which mutant myocilin accumulates in the endoplasmic reticulum (ER) leading to ER stress and trabecular meshwork (TM) cell death. Therefore, knocking out myocilin at the genome level is an ideal strategy to permanently cure the disease. We have previously utilized CRISPR/Cas9 genome editing successfully to target MYOC using adenovirus 5 (Ad5). However, Ad5 is not a suitable vector for clinical use. Here, we sought to determine the efficacy of adeno-associated viruses (AAVs) and lentiviruses (LVs) to target the TM. First, we examined the TM tropism of single-stranded (ss) and self-complimentary (sc) AAV serotypes as well as LV expressing GFP via intravitreal (IVT) and intracameral (IC) injections. We observed that LV_GFP expression was more specific to the TM injected via the IVT route. IC injections of Trp-mutant scAAV2 showed a prominent expression of GFP in the TM. However, robust GFP expression was also observed in the ciliary body and retina. We next constructed lentiviral particles expressing Cas9 and guide RNA (gRNA) targeting MYOC (crMYOC) and transduction of TM cells stably expressing mutant myocilin with LV_crMYOC significantly reduced myocilin accumulation and its associated chronic ER stress. A single IVT injection of LV_crMYOC in Tg-MYOCY437H mice decreased myocilin accumulation in TM and reduced elevated IOP significantly. Together, our data indicates, LV_crMYOC targets MYOC gene editing in TM and rescues a mouse model of myocilin-associated glaucoma.
Keywords: ER stress; Gene therapy; Genome editing for glaucoma; Intraocular pressure; Lentiviral particles; Myocilin-associated Glaucoma; Trabecular meshwork; Viral vectors.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures





Update of
-
Lentiviral mediated delivery of CRISPR/Cas9 reduces intraocular pressure in a mouse model of myocilin glaucoma.Res Sq [Preprint]. 2023 Dec 19:rs.3.rs-3740880. doi: 10.21203/rs.3.rs-3740880/v1. Res Sq. 2023. Update in: Sci Rep. 2024 Mar 23;14(1):6958. doi: 10.1038/s41598-024-57286-6. PMID: 38196579 Free PMC article. Updated. Preprint.
Similar articles
-
Lentiviral mediated delivery of CRISPR/Cas9 reduces intraocular pressure in a mouse model of myocilin glaucoma.Res Sq [Preprint]. 2023 Dec 19:rs.3.rs-3740880. doi: 10.21203/rs.3.rs-3740880/v1. Res Sq. 2023. Update in: Sci Rep. 2024 Mar 23;14(1):6958. doi: 10.1038/s41598-024-57286-6. PMID: 38196579 Free PMC article. Updated. Preprint.
-
Expression of Mutant Myocilin Induces Abnormal Intracellular Accumulation of Selected Extracellular Matrix Proteins in the Trabecular Meshwork.Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):6058-6069. doi: 10.1167/iovs.16-19610. Invest Ophthalmol Vis Sci. 2016. PMID: 27820874 Free PMC article.
-
Topical ocular sodium 4-phenylbutyrate rescues glaucoma in a myocilin mouse model of primary open-angle glaucoma.Invest Ophthalmol Vis Sci. 2012 Mar 21;53(3):1557-65. doi: 10.1167/iovs.11-8837. Print 2012 Mar. Invest Ophthalmol Vis Sci. 2012. PMID: 22328638 Free PMC article.
-
Targeting the ER-autophagy system in the trabecular meshwork to treat glaucoma.Exp Eye Res. 2016 Mar;144:38-45. doi: 10.1016/j.exer.2015.08.017. Epub 2015 Aug 22. Exp Eye Res. 2016. PMID: 26302411 Free PMC article. Review.
-
Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension.Cochrane Database Syst Rev. 2022 Jun 10;6(6):CD013817. doi: 10.1002/14651858.CD013817.pub2. Cochrane Database Syst Rev. 2022. PMID: 35686679 Free PMC article.
Cited by
-
Protein misfolding and mitochondrial dysfunction in glaucoma.Front Cell Dev Biol. 2025 Apr 25;13:1595121. doi: 10.3389/fcell.2025.1595121. eCollection 2025. Front Cell Dev Biol. 2025. PMID: 40385286 Free PMC article. Review.
-
Gene therapy for glaucoma: Targeting key mechanisms.Vision Res. 2024 Dec;225:108502. doi: 10.1016/j.visres.2024.108502. Epub 2024 Oct 18. Vision Res. 2024. PMID: 39423611 Free PMC article. Review.
-
Subconjunctival Administration of an Adeno-Associated Virus Expressing Stanniocalcin-1 Provides Sustained Intraocular Pressure Reduction in Mice.Ophthalmol Sci. 2024 Jul 31;5(1):100590. doi: 10.1016/j.xops.2024.100590. eCollection 2025 Jan-Feb. Ophthalmol Sci. 2024. PMID: 39328825 Free PMC article.
-
Impaired axonal transport contributes to neurodegeneration in a Cre-inducible mouse model of myocilin-associated glaucoma.JCI Insight. 2025 Jan 21;10(5):e188710. doi: 10.1172/jci.insight.188710. JCI Insight. 2025. PMID: 39836483 Free PMC article.
-
CRISPR-Cas9 in the Tailoring of Genetically Engineered Animals.Curr Issues Mol Biol. 2025 May 4;47(5):330. doi: 10.3390/cimb47050330. Curr Issues Mol Biol. 2025. PMID: 40699729 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous